Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

被引：6
|
作者：
Maruyama, Dai [1 ]
Nagai, Hirokazu [2 ]
Fukuhara, Noriko [3 ]
Kitano, Toshiyuki [4 ]
Ishikawa, Takayuki [5 ]
Nishikawa, Tomoaki [6 ]
机构：
[1] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[2] Natl Hosp Org Nagoya Med Ctr, Dept Hematol, Nagoya, Aichi, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto, Japan
[5] Kobe City Med Ctr Gen Hosp, Dept Hematol, Kobe, Hyogo, Japan
[6] Janssen Pharmaceut KK, Tokyo, Japan
来源：
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY | 2019年 / 59卷 / 02期
关键词：
covalent BTK inhibitor; ibrutinib; Japanese patients; mantle cell lymphoma; phase II clinical trial;
D O I：
10.3960/jslrt.19006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：98 / 100
页数：3
相关论文
共 50 条
  • [31] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul J.
    Koenig, Patricia A.
    Inwards, David J.
    Shah, Keith
    Ziesmer, Steven C.
    Feldman, Andrew L.
    Rao, Radha
    Gupta, Mamta
    Erlichman, Charles
    Witzig, Thomas E.
    LANCET ONCOLOGY, 2011, 12 (04): : 361 - 368
  • [32] Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Wang, Michael
    Oki, Yasuhiro
    Pro, Barbara
    Romaguera, Jorge Enrique
    Rodriguez, Maria Alma
    Samaniego, Felipe
    McLaughlin, Peter
    Hagemeister, Frederick
    Neelapu, Sattva
    Copeland, Amanda
    Samuels, Barry I.
    Loyer, Evelyne M.
    Ji, Yuan
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) : 5213 - 5218
  • [33] Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
    Zhang, Yuchen
    Liu, Panpan
    Cai, Jun
    Jing, Hongmei
    Zou, Liqun
    Huang, Huiqiang
    Wu, Yuanbin
    Li, Wenyu
    Zhong, Liye
    Jin, Xueli
    Ye, Xu
    Feng, Ru
    Zhang, Huilai
    Zhang, Liling
    Lin, Lie
    Sun, Xiuhua
    Tian, Yuyang
    Xia, Zhongjun
    Li, Zhiming
    Huang, He
    Xia, Yi
    Cai, Qingqing
    CANCER MEDICINE, 2022, 11 (22): : 4134 - 4145
  • [34] Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Alrawashdh, Neda
    Alkhatib, Nimer
    McBride, Ali
    Persky, Daniel
    Abraham, Ivo
    BLOOD, 2018, 132
  • [35] ECONOMIC EVALUATION OF IBRUTINIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA IN MEXICO
    Carlos, F.
    Herrera, M.
    Salazar, A.
    Aguirre, A.
    Gonzalez-Michaca, L.
    VALUE IN HEALTH, 2016, 19 (03) : A249 - A249
  • [36] Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
    Dreyling, Martin
    Jurczak, Wojciech
    Jerkeman, Mats
    Silva, Rodrigo Santucci
    Rusconi, Chiara
    Trneny, Marek
    Offner, Fritz
    Caballero, Dolores
    Joao, Cristina
    Witzens-Harig, Mathias
    Hess, Georg
    Bence-Bruckler, Isabelle
    Cho, Seok-Goo
    Bothos, John
    Goldberg, Jenna D.
    Enny, Christopher
    Traina, Shana
    Balasubramanian, Sriram
    Bandyopadhyay, Nibedita
    Sun, Steven
    Vermeulen, Jessica
    Rizo, Aleksandra
    Rule, Simon
    LANCET, 2016, 387 (10020): : 770 - 778
  • [37] Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
    Phillips, Tycel Jovelle
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Trneny, Marek
    Bartlett, Nancy L.
    Zaucha, Jan
    Wrobel, Tomasz
    Offner, Fritz
    Humphrey, Kathryn
    Relf, James
    de L'Etang, Audrey Filezac
    Carlile, David J.
    Byrne, Ben
    Qayum, Naseer
    Lundberg, Linda
    Dickinson, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
  • [38] A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Luhua
    Fayad, Luis
    Hagemeister, Fredrick B.
    Neelapu, Sattva
    Samaniego, Felipe
    McLaughlin, Peter
    Samuels, Barry
    Yi, Qing
    Pro, Barbara
    Fanale, Michelle
    Shah, Jatin
    Younes, Anas
    Bell, Neda
    Knight, Robert
    Zeldis, Jerome B.
    Cabanillas, Fernando
    Kwak, Larry
    Romaguera, Jorge
    BLOOD, 2009, 114 (22) : 1064 - 1065
  • [39] Phase I/II Clinical Trial of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, and Follicular Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 17 - 18
  • [40] Ibrutinib for relapsed/refractory mantle cell lymphoma: 7-year experience
    Grilo, I. T.
    Couto, M. E.
    Freitas, J. F.
    Pereira, D. P.
    Moreira, C.
    Chacim, S.
    Domingues, N.
    Santo, A. E.
    Martins, A.
    Viterbo, L.
    Oliveira, I.
    Moreira, I.
    Mariz, J. M.
    ANNALS OF ONCOLOGY, 2019, 30
12345